Sponsor

Clementia Pharmaceuticals Inc. An Ipsen Company

1155 Metcalfe Street Suite 1500, H3B 2V6

About the sponsor

Clinical research is centered on fibrodysplasia ossificans progressiva, a rare disorder marked by progressive heterotopic ossification in both adult and paediatric participants.

Heterotopic ossification
Rare disease research
Adult and paediatric care

The sponsor’s trial activity in this area reflects a focused interest in conditions affecting abnormal bone formation and the clinical burden associated with progressive connective tissue pathology.

About Specializations

Clementia Pharmaceuticals Inc. An Ipsen Company runs clinical trials in conditions such as Fibrodysplasia ossificans progressiva, among others.

Fibrodysplasia ossificans progressiva

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

1 clinical trial

Fibrodysplasia ossificans progressiva

Not recruiting

Investigational

Study on the Effects of Fidrisertib for Treating Fibrodysplasia Ossificans Progressiva in Children and Adults

Investigational

Belgium

Participants:0–17 years · 18–64 years · 65+ years
Substances:(R)‑Tetrahydrofuran‑3‑Yl 4‑(6‑(5‑(4‑Ethoxy‑1‑Isopropylpiperidin‑4‑Yl)Pyridin-2-Yl)Pyrrolo[1,2-B]Pyridazin-4-Yl)Piperazine-1-Carboxylate Sesquisuccinate
Sponsor:Clementia Pharmaceuticals Inc. An Ipsen Company

Contact Research Centre

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →